Vista0.3%

Vista 0.3% tablets are indicated for the treatment of adults with mild to moderate infections caused by susceptible strains. Lower Respiratory Tract: Acute bacterial exacerbation of chronic bronchitis lung abscess, pneumonia. Gastrointestinal Tract: Enteric fever, shigellosis. ... Read moreVista 0.3% tablets are indicated for the treatment of adults with mild to moderate infections caused by susceptible strains. Lower Respiratory Tract: Acute bacterial exacerbation of chronic bronchitis lung abscess, pneumonia. Gastrointestinal Tract: Enteric fever, shigellosis. Multi-drug-resistant Tuberculosis. Skin and skin structures: Uncomplicated skin and skin structure infections. Sexually Transmitted Diseases: Acute, Uncomplicated urethral and cervical gonorrhoea. Nongonococcal urethritis and cervicitis. Mixed infections of the urethra and cervix. Urinary tract: Uncomplicated Urinary Tract Infections, Complicated urinary tract infections. Vista 0.3% Eye & Ear Drops is indicated in- Eye: It is indicated for the treatment of external ocular infections such as acute & sub-acute conjunctivitis, keratitis, kerato-conjunctivitis, blepharo-conjunctivitis, blepharitis, corneal ulcer and pre-operative prophylaxis in ocular surgery. Ear: It is indicated for the treatment of external ear infections (otitis externa) and certain middle ear infections (otitis media).

4-Quinolone preparations, Aural Anti-bacterial preparations

Vista 0.3% is a synthetic 4-fluoroquinolone antibacterial agent with bactericidal activity against a wide range of Gram-negative and Gram-positive organisms. Vista 0.3% is thought to exert bactericidal effect by inhibiting DNA gyrase, an essential enzyme that is a critical catalyst in the duplication, transcription and repair of bacterial DNA.

General dosage recommendations: The dose of Vista 0.3% is determined by the type and severity of the infection. The dosage range for adults is 200 mg to 800 mg daily. Up to 400 mg may be given as a single dose, preferably in the morning, larger doses should be given as two divided doses. Vista 0.3% tablets should be swallowed with liquid; they should not be taken within two hours of intake of magnesium/aluminium containing antacids or iron preparations since reduction of absorption of Vista 0.3% can occur. Enteric fever: For adults 200 mg, every 12 hours, for 5 days. For children 15 mg/kg/day in 2 divided doses for 3 days. Shigellosis: 400 mg single dose. Multi-drug-resistant tuberculosis: 400 mg twice daily along with conventional  anti-tuberculosis drugs. Lower respiratory tract infection: 400 mg daily, increasing, if necessary, to 400 mg twice daily. Uncomplicated Urinary Tract Infections: A single dose of 200/400 mg. Uncomplicated urethral and cervical gonorrhoea: A single dose of 400 mg. Non-gonococcal urethral and cervicitis: 400 mg daily in single or divided doses. Complicated Urinary Tract Infection: 200/400 mg/day for 7 days. Impaired liver function: The excretion of Vista 0.3% may be reduced inpatients with severe hepatic dysfunction. Children: Vista 0.3% is usually not indicated for use in children or growing adolescents. Elderly: No adjustment of dosage is required in the elderly. Vista 0.3% Eye & Ear Drops- Eye: Instill 1 drop in the affected eye(s) every 2 to 4 hours for the first two days and then 4 times daily. The length of treatment should not exceed ten days. Ear: Instill 1-2 drops in the affected ear(s) twice daily or as needed.

May be taken with or without food. Avoid antacids or supplements containing Fe or Zn within 2 hr before or after Vista 0.3%. Ensure adequate hydration.

Antacids containing magnesium, aluminium or calcium may decrease absorption of Vista 0.3%. Iron or Zinc may decrease oral absorption of Vista 0.3%.

Vista 0.3% should not be used in-patients with known hypersensitivity to 4-fluoroquinolone antibacterials. It is contraindicated in-patients with a history of epilepsy or with a lowered seizure threshold. Vista 0.3% is usually contraindicated in children or growing adolescents and in pregnant or breast feeding women.

Vista 0.3% tablet is generally well tolerated and clinical side-effects of Vista 0.3% has been quite low. Among the adverse effects gastrointestinal and central nervous systems' reactions are common. Nausea, rash, vomiting, abdominal pain, diarrhoea and gastrointestinal distress are the gastrointestinal adverse effects. Common central nervous system reactions are headache, dizziness and insomnia.Eye: Transient ocular irritation, burning, stinging, redness, itching or photophobia have been reported.Ear: Mild irritation or mild discomfort in the ear may occur. Symptoms of an allergic reaction include rash, itching, swelling or trouble breathing.

The safety of Vista 0.3% during pregnancy has not been established. Vista 0.3% may enter breast milk but data are not available.

Patients being treated with Vista 0.3% should not expose themselves unnecessarily to strong sunlight and should avoid UV rays. Caution is recommended if the drug is to be used in psychotic patients or in-patients with a history of psychiatric disease.Prolonged use of eye drops & ear drops may result in overgrowth of non-susceptible organisms and secondary infection respectively.

Symptoms: Confusion, dizziness, impairment of consciousness, convulsive seizures, GI reactions (e.g. nausea, mucosal erosions). Management: Symptomatic and supportive treatment. Remove any unabsorbed drug by gastric lavage or admin of adsorbants and Na sulfate. Antacids are recommended for protection of gastric mucosa. Elimination may be increased by forced diuresis.

Store between 15-30°C. Protect from light.

Renal Impairment: CrCl <20 and patients on haemodialysis or peritoneal dialysis: 100 mg 24 hrly following usual initial dose. CrCl 20-50: Reduce dose by half 24 hrly following usual initial dose. Hepatic Impairment:Severe: Reduce dose. Max: 400 mg daily

4-Quinolone preparations, Aural Anti-bacterial preparations

Vista 0.3% containing Vista 0.3% is a synthetic 4-fluoroquinolone antibacterial agent with bactericidal activity against a wide range of Gram-negative and Gram-positive organisms. Vista 0.3% is thought to exert bactericidal effect by inhibiting DNA gyrase, an essential enzyme that is a critical catalyst in the duplication, transcription and repair of bacterial DNA. Following oral administration Vista 0.3% is rapidly and well absorbed from G.I. tract. The bioavailability of Vista 0.3% in the tablet formulation is almost 100%. It is widely distributed into body tissues and fluid. The half-life is about 4.6 to 6.9 hours. Up to 80% of an oral dose of Vista 0.3% is eliminated in the urine as the parent compound within 48 hour.

The safety of Vista 0.3% during pregnancy has not been established. Vista 0.3% may enter breast milk but data are not available.